Literature DB >> 11999982

Tetrahydrobiopterin responsiveness in phenylketonuria. Two new cases and a review of molecular genetic findings.

U Lässker1, J Zschocke, N Blau, R Santer.   

Abstract

We report two new patients with tetrahydrobiopterin (BH4)-responsive phenylketonuria and compare their phenylalanine hydroxylase (PAH) genotypes (A395P/ IVS12+g>a and R261Q/165T, respectively) to those of previous cases from the literature. These case observations confirm earlier reports stating that BH4-responsive patients are frequently carriers of a missense mutation within the DNA region coding for the catalytic domain of the enzyme. Interestingly, many of the PAH gene mutations detected in BH4-responsive patients have been associated with an inconsistent phenotype in the past. Our case reports confirm that it is necessary to thoroughly examine individuals with increased phenylalanine levels, not only to detect BH4 deficiency, but also to identify patients with PAH deficiency who may benefit from BH4 treatment. In both of our patients, however, an effect of BH4 (7.5 mg/kg) on plasma phenylalanine levels was not seen in the newborn period. We therefore conclude that a normal neonatal BH4 test does not necessarily exclude BH4 responsiveness in all such patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11999982     DOI: 10.1023/a:1015194002487

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  7 in total

1.  Successful treatment of phenylketonuria with tetrahydrobiopterin.

Authors:  F K Trefz; C Aulela-Scholz; N Blau
Journal:  Eur J Pediatr       Date:  2001-05       Impact factor: 3.183

2.  Tetrahydrobiopterin responsiveness in phenylketonuria differs between patients with the same genotype.

Authors:  M Lindner; D Haas; E Mayatepek; J Zschocke; P Burgard
Journal:  Mol Genet Metab       Date:  2001-05       Impact factor: 4.797

Review 3.  Crystal structure of the catalytic domain of human phenylalanine hydroxylase reveals the structural basis for phenylketonuria.

Authors:  H Erlandsen; F Fusetti; A Martinez; E Hough; T Flatmark; R C Stevens
Journal:  Nat Struct Biol       Date:  1997-12

Review 4.  A structural hypothesis for BH4 responsiveness in patients with mild forms of hyperphenylalaninaemia and phenylketonuria.

Authors:  H Erlandsen; R C Stevens
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

5.  Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.

Authors:  S Kure; D C Hou; T Ohura; H Iwamoto; S Suzuki; N Sugiyama; O Sakamoto; K Fujii; Y Matsubara; K Narisawa
Journal:  J Pediatr       Date:  1999-09       Impact factor: 4.406

6.  Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations.

Authors:  E Kayaalp; E Treacy; P J Waters; S Byck; P Nowacki; C R Scriver
Journal:  Am J Hum Genet       Date:  1997-12       Impact factor: 11.025

7.  Crystal structure and site-specific mutagenesis of pterin-bound human phenylalanine hydroxylase.

Authors:  H Erlandsen; E Bjørgo; T Flatmark; R C Stevens
Journal:  Biochemistry       Date:  2000-03-07       Impact factor: 3.162

  7 in total
  8 in total

1.  Large neutral amino acids in the treatment of phenylketonuria (PKU).

Authors:  R Matalon; K Michals-Matalon; G Bhatia; E Grechanina; P Novikov; J D McDonald; J Grady; S K Tyring; F Guttler
Journal:  J Inherit Metab Dis       Date:  2006-09-21       Impact factor: 4.982

2.  The spectrum of phenylalanine variations under tetrahydrobiopterin load in subjects affected by phenylalanine hydroxylase deficiency.

Authors:  V Leuzzi; C Carducci; C Carducci; F Chiarotti; C Artiola; T Giovanniello; I Antonozzi
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

Review 3.  Phenylketonuria as a model for protein misfolding diseases and for the development of next generation orphan drugs for patients with inborn errors of metabolism.

Authors:  Ania C Muntau; Søren W Gersting
Journal:  J Inherit Metab Dis       Date:  2010-09-08       Impact factor: 4.982

4.  Pharmacokinetics of orally administered tetrahydrobiopterin in patients with phenylalanine hydroxylase deficiency.

Authors:  M R Zurflüh; L Fiori; B Fiege; I Ozen; M Demirkol; K H Gärtner; B Thöny; M Giovannini; N Blau
Journal:  J Inherit Metab Dis       Date:  2006-11-07       Impact factor: 4.982

5.  Significance of genotype in tetrahydrobiopterin-responsive phenylketonuria.

Authors:  F K Trefz; D Scheible; H Götz; G Frauendienst-Egger
Journal:  J Inherit Metab Dis       Date:  2008-10-30       Impact factor: 4.982

6.  Effect of BH(4) supplementation on phenylalanine tolerance.

Authors:  A Burlina; N Blau
Journal:  J Inherit Metab Dis       Date:  2008-12-09       Impact factor: 4.982

7.  Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine.

Authors:  R Matalon; K Michals-Matalon; G Bhatia; A B Burlina; A P Burlina; C Braga; L Fiori; M Giovannini; E Grechanina; P Novikov; J Grady; S K Tyring; F Guttler
Journal:  J Inherit Metab Dis       Date:  2007-02-27       Impact factor: 4.750

8.  First Case Report of EX3del4765 Mutation in PAH Gene in Asian Population.

Authors:  Ziba Soltani; Fatemeh Karami; Vahidreza Yassaee; Feyzollah Hashemi Gorji; Mahdieh Talebzadeh; Mohammad Miryounesi
Journal:  Iran Red Crescent Med J       Date:  2016-01-01       Impact factor: 0.611

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.